Primary cutaneous anaplastic large cell lymphoma successfully treated with local thermotherapy using pocket hand warmers

Journal of Dermatology

Volumn 35, Issue 11, 2008, Pages 748-750

  Honma, Masaru ^a   Hashimoto, Makoto ^a   Iwasaki, Takeshi ^a   Iinuma, Shin ^a   Takahashi, Hidetoshi ^a   Ishida Yamamoto, Akemi ^a   Iizuka, Hajime ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Anaplastic large cell lymphoma; Caspase 3; Heat shock protein 90

Indexed keywords

HEAT SHOCK PROTEIN 90; THYMIDINE KINASE;

AGED; APOPTOSIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; LARGE CELL LYMPHOMA; MALE; PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA; SKIN LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR REGRESSION;

AGED, 80 AND OVER; HUMANS; HYPERTHERMIA, INDUCED; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 57449104703     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2008.00560.x     Document Type: Article

References (13)

1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005 105 : 3768 3785.
2. Grange F, Hedelin G, Joly P et al. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sezary syndrome. The French Study Group on Cutaneous Lymphomas. Blood 1999 93 : 3637 3642.
3. Stein H, Foss HD, Dürkop H et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000 96 : 3681 3695.
4. Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000 95 : 3653 3661.
5. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 2003 49 : 1049 1058.
6. Yanase K, Yamada M. "Pocket-warmer" therapy of chromomycosis. Arch Dermatol 1978 114 : 1095.
7. Hisamichi K, Hiruma M, Yamazaki M, Matsushita A, Ogawa H. Efficacy of oral minocycline and hyperthermic treatment in a case of atypical mycobacterial skin infection by Mycobacterium marinum. J Dermatol 2002 29 : 810 811.
8. Urabe H. Local hyperthermia. Jpn J Clin Dermatol 1989 43 : 638 641 (in Japanese).
9. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002 62 : 1559 1566.
10. Bonvini P, Dalla Rosa H, Vignes N, Rosolen A. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 2004 64 : 3256 3264.
11. Valbuena JR, Rassidakis GZ, Lin P et al. Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod Pathol 2005 18 : 1343 1349.
12. Duval A, Olaru D, Campos L, Flandrin P, Nadal N, Guyotat D. Expression and prognostic significance of heat-shock proteins in myelodysplastic syndromes. Haematologica 2006 91 : 713 714.
13. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005 5 : 761 772.